Drug Trial Radar · NCT03901105
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Aug 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Mar 28, 2019
Primary completion
Apr 28, 2019
Study completion Apr 28, 2019
Sponsor
- Lead sponsor
- Avid RadiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).
Conditions
- Alzheimer Disease
Interventions
flortaucipir F18Drug
No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
Brain PET ScanProcedure
positron emission tomography (PET) scan of the brain
Primary outcomes
What the sponsor says the trial is designed to measure.
- Risk Ratio for AD Symptom Progression on CDR-SBTime frame: Within 18 months of scan
Locations
1 site in 1 country. Site status is shown where the registry gives one.
American College of Radiology
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.